CervoMed Q4 and update

 -Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure-

-Plan to initiate Phase 3 trial in mid-2026 following meeting with regulatory authorities-

-Awarded 2024 Prix Galien USA Award as “Best Startup” by the Galien Foundation-

https://www.globenewswire.com/news-release/2025/03/17/3043647/0/en/CervoMed-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Corporate-Updates.html